New study tests Weight-Loss drug in rare obesity conditions
NCT ID NCT06901245
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tests the weight-loss drug tirzepatide in young adults aged 18-26 with Prader-Willi syndrome, hypothalamic obesity, or general obesity. Participants take the medication for one year to see how much weight they lose and how other health measures change. The goal is to see if the drug works as well in these rare conditions as it does in general obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Children's Minnesota
RECRUITINGSaint Paul, Minnesota, 55102, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.